Cohance Lifesciences Q2 FY27 Results Set for November 6

Cohance Lifesciences Limited will consider its Q2 FY27 results on November 6, 2026, after Q1 sales declined 23.1% year on year to ₹422.26 crore and the company reported a net loss of ₹45.19 crore. The board meeting and subsequent management call will provide the next update on expected sequential recovery.

When will Cohance report its Q2 FY27 results?

Cohance will hold a board meeting on Friday, November 6, 2026, to consider and approve its financial results for the July-September 2026 quarter. The date was disclosed in the company's October 26 filing with the NSE. The September quarter is the second quarter of FY27 and follows a weak June-quarter performance.

Cohance has also rescheduled its investor and analyst conference call to 6:00 p.m. IST on November 6, from the previously announced 6:30 p.m. IST timing. Management is expected to discuss the unaudited Q2 and H1 FY27 financial results and take questions from investors and analysts. The company said dial-in facilities would be available for global participants.

The results are due 37 days after the September-quarter end, according to the reported results calendar. As of the information provided, the Q2 FY27 results had not yet been filed on the NSE. The board meeting and conference call therefore represent the next formal disclosures on revenue, profitability, order execution and operating conditions.

What did Cohance report in Q1 FY27?

Cohance reported June-quarter net sales turnover of ₹422.26 crore, down from ₹549.31 crore in the corresponding quarter a year earlier and ₹619.12 crore in the preceding March 2026 quarter. Total income was ₹434.51 crore, compared with ₹563.48 crore in June 2025.

The June-quarter figures showed a sharp compression in operating performance. Operating profit was ₹1.16 crore, compared with ₹112.01 crore a year earlier, while reported EBITDA was ₹13.41 crore versus ₹126.18 crore. The company recorded a loss of ₹45.19 crore, against a profit of ₹54.50 crore in the year-earlier quarter. Basic earnings per share moved to a loss of ₹0.63 from a profit of ₹1.28.

Management described Q1 FY27 as a guided trough quarter. On an adjusted basis, it reported EBITDA of ₹9.2 crore, or ₹92 million, on consolidated revenue of ₹422.3 crore, or ₹4,223 million. The company attributed the timing pressure to shipments being phased into later quarters and said commercial deliveries, restocking orders and better platform utilisation were expected to support improvement.

Why did Cohance's June-quarter performance weaken?

Cohance's Q1 FY27 revenue was affected by shipment timing, with management indicating that deliveries were scheduled to fall in later quarters. The company has said it expects sequential improvement from Q2 and a return to year-on-year growth in the second half of FY27, supported by secured orders, scheduled commercial deliveries and restocking demand.

The June-quarter cost structure also weighed on profitability. Total expenses were ₹421.10 crore, leaving limited operating profit despite total income of ₹434.51 crore. EBIT was negative ₹36.13 crore, compared with positive ₹81.04 crore in June 2025. Interest expense was ₹6.74 crore and the pre-tax loss was ₹42.87 crore.

The broader operating context includes pressure in the contract development and manufacturing business. Earlier company disclosures cited shipment deferrals, inventory normalisation and delays in customer product approvals as factors affecting performance. Industry conditions have also been affected by funding constraints among biotechnology customers, which can influence project progression and ordering patterns.

Cohance reported FY26 revenue of ₹2,268.6 crore, down 13% from the previous year, while adjusted EBITDA declined 45.6% to ₹477.5 crore. The figures provide context for management's focus on delivery execution, utilisation and customer conversions as it seeks to improve the pace of growth in FY27.

What should investors examine in the Q2 FY27 announcement?

Investors will examine whether Cohance delivered the sequential revenue improvement management outlined after the June-quarter results. Revenue movement will be particularly relevant because Q1 sales were 31.8% below the March 2026 quarter, based on the reported quarterly figures. Any update on commercial shipment schedules and restocking orders will help explain the progression of revenue through the first half.

Profitability will be another important measure after the substantial year-on-year reduction in Q1 operating profit and EBITDA. The June-quarter operating margin was reported at 0.3%, reflecting the impact of lower sales and the cost base. Investors will also assess whether the company provides information on utilisation levels, customer demand and the trajectory of margins in the second half.

The company has previously indicated capital expenditure of ₹300 crore focused on antibody-drug conjugates and oligonucleotides. Updates on the timing, scope and funding of this investment could matter for the platform's capacity development. However, the disclosed information does not provide a revised FY27 financial target.

The Q2 release will also cover the first half of FY27. That makes the November 6 discussion relevant for assessing the gap between first-half performance and management's stated expectation of year-on-year recovery in H2 FY27. The company has not yet released the September-quarter figures, so revenue, profit and cash-flow outcomes remain pending until the board approval.

Conclusion

Cohance enters its Q2 FY27 result announcement after a June quarter in which sales fell 23.1% year on year to ₹422.26 crore and the company moved to a ₹45.19 crore loss. The November 6 disclosures will show whether scheduled shipments and restocking activity began to reverse the weak first-quarter trend.

The key points to watch are the Q2 revenue trajectory, margin movement, delivery execution and management's commentary on H2 FY27 growth. Cohance has stated that sequential improvement should begin from Q2 and that year-on-year recovery is expected in the second half, with the investor call at 6:00 p.m. IST scheduled to provide further detail.